Scarica l'app Stockscreener
36.69
0.14%
-0.05
Dopo l'orario di chiusura:
36.69
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold? - Yahoo Finance
Cantor Fitzgerald reiterates Ideaya Biosciences stock rating By Investing.com - Investing.com Canada
How (IDYA) Movements Inform Risk Allocation Models - Stock Traders Daily
IDEAYA Biosciences stock gains attention as IDE-849 moves toward Phase 3 - ad-hoc-news.de
IDEAYA Biosciences at Morgan Stanley conference: darovasertib leads push By Investing.com - Investing.com Canada
IDYA: Precision oncology pipeline advances with darovasertib, DLL3 ADC, and MTAP/KRAS programs - TradingView
Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65 - Moomoo
IDEAYA at citigroup’s biopharma back to school summit 2026: pipeline breadth - Investing.com Canada
IDYA: NDA submission, ESMO data, and Roche collaborations set the stage for major oncology advances - TradingView
Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE) - The Globe and Mail
IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push - Investing.com
IDEAYA Biosciences Doses First Patient in Phase 3 Trial - grafa.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data - Investing.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data By Investing.com - Investing.com Canada
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - PR Newswire
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com Nigeria
Phase III path opens for Ideaya’s IDE-849 in DLL3 ADC horse race - BioWorld News
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - theglobeandmail.com
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress By Investing.com - Investing.com Nigeria
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - 富途牛牛
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress - Investing.com
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer - PR Newswire
IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy - Yahoo Finance
IDEAYA Biosciences (IDYA) Slips 2.3% to $40.81 as Biotech Momentum FadesMomentum Factor - vinanet.vn
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Nigeria
Ideaya Biosciences stock hits 52-week high at 40.88 USD - Investing.com
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA) - Seeking Alpha
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Eastern Progress
IDEAYA (IDYA) Close: Adds 1.43% to Close at $39.67 at the Close; Technical Setup: the Near-Term Reference Band Stretches From $37.69 to $41.65 in the Available RecordOption Strike Build - careplusvn.com
Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA (IDYA) Results Check: The EPS Result Is Below Expectation in Latest Trading; Shares Close 2.48% Higher for the Current SessionEarnings Miss Alert - Vinanet
symbol__ Stock Quote Price and Forecast - CNN
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com - Investing.com South Africa
IDEAYA partners with Genentech on pancreatic cancer trial - Investing.com
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire
Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences (IDYA) Cash Flow Statement - Moomoo
Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants - Stock Titan
IDEAYA Biosciences (IDYA) Holds Near $37 as Bulls Eye Breakout Above $38.81 ResistanceVolume Breakout Ideas - Vinanet
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62 - Moomoo
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Exploring a 41.95% Potential Upside in Precision Medicine - DirectorsTalk Interviews
IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup - ChartMill
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Strong Position To Grow Its Business - Moomoo
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership - Yahoo Finance
IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59 - Moomoo
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60 - Moomoo
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):